Bulk Anti-Human CD8 (UCHT-4) Antibody

Product Specifications

Background

Anti-CD8 may be used in studies of immunoregulation and T-lymphocyte mediated suppression, autoimmune disorders, immunodeficiency states and acute lymphoblastic leukemia and lymphoma.

Host

Mouse

Reactivity

Human

Target

CD8

Isotype

IgG2a

Clone

UCHT-4

Applications

Flow Cytometry, Western Blot, Immunoprecipitation, Functional Assays, IHC, Immunofluorescence, ELISA

Purification Method

This monoclonal antibody was purified using Protein A

Concentration

1.0 - 5.0 mg/mL

Endotoxin

<1.0 EU/mg as determined by the LAL method

Purity

>95% by SDS-PAGE and HPLC

Buffer

ICH3001-100ml ICH3002-100ml ICH3003-100ml

Shipping Conditions

Blue ice

Storage Conditions

Anti-CD8 In Vivo Antibody - Low Endotoxin (UCHT-4) is stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Specificity

Anti-CD8 In Vivo Antibody - Low Endotoxin (UCHT-4) recognizes Human CD8. Anti-Human CD8 recognizes a T-cell glycoprotein cell surface complex (Mr 32 kDa) which defines the cytotoxic/suppressor population of mature T-lymphocytes. The CD8 complex interacts with class I MHC molecules resulting in increased adhesion between CD8+ T-lymphocytes and their target cells. Binding of the CD8 antigen to Class I MHC molecules enhances T-cell activation. The cytoplasmic portion of the CD8 antigen is associated with a protein tyrosine kinase (p56lck) .

Formulation

0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.

Antigen Distribution

The CD8 antigen is expressed on approximately 19-48% of normal human peripheral blood lymphocytes and > 90% of normal thymocytes. It is also present on a subset of NK cells. Subjects infected with HIV have been shown to exhibit increased levels of CD8+ lymphocytes with a continual decrease in CD4+ lymphocytes.